+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comparison of interferon monotherapy with interferon-lamivudine combination treatment in children with chronic hepatitis B



Comparison of interferon monotherapy with interferon-lamivudine combination treatment in children with chronic hepatitis B



Indian Journal of Gastroenterology 25(3): 136-139



To compare interferon monotherapy with combination treatment using interferon and lamivudine in children with chronic hepatitis B. Data from 65 children who had received either interferon-alpha (5 MU/m2 subcutaneous thrice a week for 6 months; n=35; Group 1) or this dose of interferon-alpha for 6 months with oral lamivudine for one year (4 mg/Kg/day, maximum 100 mg/day; n=30; Group 2) were analyzed retrospectively. Complete response was defined as ALT normalization, HBeAg/anti-HBe seroconversion and HBV DNA clearance. ALT normalization rates were similar in Groups 1 and 2 at the end of interferon treatment (13 [38%] and 16 [52%], respectively), at 12 months (19 [56%] and 18 [58%]) and at 24 months (24 [71%] and 23 [74%]). HBV DNA clearance was more frequently observed at 6 months in Group 2 than in Group 1 (19 [63%] versus 7 [20%]; p=0.01), but not at 12 months (19 [63%] versus 17 [49%]) or at 24 months (20 [67%] versus 21 [60%]). Rate of HBeAg/anti-HBe seroconversion was higher in Group 2 at 12 months (18 [60%] versus 11 [31%]; p< 0.05). Rate of complete response was similar in Groups 1 and 2 at 6 months (5 [14%] and 10 [33%], respectively), 12 months (14 [40%] and 17 [57%]) and 24 months (20 [57%] and 19 [63%]). Although lamivudine and interferon combination achieved higher initial rates of HBV DNA loss and HBeAg/anti-HBe seroconversion than interferon alone, the final response rates were similar with the two treatments. The combination treatment is therefore not indicated for chronic hepatitis B in children.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 048603750

Download citation: RISBibTeXText

PMID: 16877826


Related references

Long term efficacy of interferon and Thymosin combination in comparison to lamivudine+interferon and interferon monotherapy in patients with HBeAg negative chronic hepatitis B. Journal of Hepatology 38(Suppl. 2): 169, 2003

Lamivudine monotherapy and interferon plus lamivudine combination therapy in anti-HBe positive patients with chronic hepatitis B who have failed previously interferon treatment. Journal of Hepatology 34(Suppl. 1): 167, 2001

Interferon alpha2a in combination with lamivudine in the treatment of patients with chronic HbeAg hepatitis B non-responders to interferon monotherapy. Journal of Hepatology 36(Suppl. 1): 245, 2002

Lamivudine monotherapy and lamivudine plus interferon alpha combination therapy in HBeAg negative chronic hepatitis B not responding to previous interferon alpha monotherapy. Acta Gastro-Enterologica Belgica 70(1): 20-24, 2007

Comparison of lamivudine monotherapy with lamivudine plus interferon alpha combination in patients with HBeAg positive chronic hepatitis B. Journal of Hepatology 34(Suppl. 1): 177-178, 2001

Combination of pegylated interferon and lamivudine is superior to lamivudine monotherapy in the treatment of chronic hepatitis B A randomized Trial. Journal of Hepatology 38(Suppl. 2): 33, 2003

Comparison of 12-month courses of interferon-alpha-2b-lamivudine combination therapy and interferon-alpha-2b monotherapy among patients with untreated chronic hepatitis B. Clinical Infectious Diseases 36(12): 1516-1522, 2003

A 12 months course of interferon and lamivudine combination therapy versus interferon monotherapy for untreated chronic hepatitis B infection. Journal of Hepatology 36(Suppl. 1): 138, 2002

Effectiveness of lamivudine and interferon-alpha combination therapy versus interferon-alpha monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial. Journal of Microbiology, Immunology, and Infection 38(4): 262-266, 2005

Combination treatment of interferon alpha-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients. Italian Journal of Gastroenterology and Hepatology 31(6): 472-475, 1999

Comparison of treatments of chronic hepatitis B in children with lamivudine and alpha-interferon combination and alpha-interferon alone. Pediatrics International 44(5): 517-521, 2002

Prospective randomized study comparing combination of pegylated interferon and lamivudine versus lamivudine monotherapy for chronic hepatitis B infection. Hepatology 36(4 Part 2): 628A, 2002

Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B. Journal of Gastroenterology and Hepatology 22(10): 1582-1588, 2007

Interferon and lamivudine combination therapy versus lamivudine monotherapy for hepatitis B e antigen-negative hepatitis B treatment: a meta-analysis of randomized controlled trials. Hepatobiliary and Pancreatic Diseases International 9(5): 462-472, 2011

Efficacy of interferon alpha-2b and lamivudine combination treatment in comparison to interferon alpha-2b alone in chronic delta hepatitis: a randomized trial. Journal of Gastroenterology and Hepatology 21(4): 657-663, 2006